GC Aesthetics® Announces Growth and Expansion in Brazil
15.6.2022 15:44:00 EEST | Business Wire | Press release
GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Women Healthcare Aesthetic and Reconstructive Solutions, has announced today, its growth and expansion plans for the Brazilian market, the second largest Breast Augmentation market in the world.
GC Aesthetics® has been executing an ambitious journey repositioning the brand and portfolio to offer a smart, unique, and clinically proven safe range of products to meet the needs of Brazilian women and surgeons.
The Brazilian growth strategy includes 2 main pillars. First, the commercialization of all GC Aesthetics® products and solutions designed to support the best outcome for women's breast enhancement journey, before, during and after surgery. This unique portfolio not only stands out in today’s industry but is aligned with the company leadership position and growing plans evolving from Breast Implant Manufacturers to Solution Providers.
The Brazilian revenue growth of GC Aesthetics® is also linked to the ANVISA certificate (Brazilian Health Regulatory Agency) just obtained for the re-introduction of The Round Collection™ Breast Implants. This unique microtextured surface breast implant has been the preferred option by surgeons in Brazil: 99% of surveyed Plastic Surgeons consider The Round Collection™ as the trustable product in terms of safety and performance.
“According to our most recent survey, long-term proven safety & the unique type of micro texture are the 2 top reasons Brazilian Plastic Surgeons prefer The Round Collection Implants against competitors. We are beyond excited to be back in Brazil with this product and offer Surgeons and Patients, a proven long-term, safe and reliable medical device. Pre-orders of this product have exceeded what we had planned, and we are looking forward to a very bright, leading future in Brazil and in the world” – said Carlos Reis Pinto, CEO of GC Aesthetics®
“At GCA®, we are dedicated to advancing the science of medical aesthetics and delivering exceptional clinical, operational and commercial performance to be the preferred partner of surgeons and physicians worldwide, we are excited for The Round Collection™ re-entry in Brazil and are excited of presenting our brand as ONE GCA” – mentioned Ron Cosmas, CCO of GCA®.
GC Aesthetics® will be presenting the re-introduction of this product at the Jornada Paulista de Cirurgia Plástica, held from June 15th to the 18th at the WTC São Paulo, Brazil. Engineered and designed for performance The Round Collection™ breast implants have an unparalled long-term safety profile. The Round Collection™ by GC Aesthetics® is part of the largest European long-term clinical study for breast implants with exceptional results at 10 years and recently had data published in a one-of-a-kind 17 year patient follow-up with remarkable patient satisfaction.
About GC Aesthetics
GC Aesthetics is a long-established global medical technology company that develops, manufactures and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal life journey.
Throughout its 40-year history, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality breast implants for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries, and our products are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness.
The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to surgeons and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005653/en/
Contact information
Fara Naomi Macias, Chief Marketing Officer
faramacias@gcaesthetics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom